Your AI-Trained Oncology Knowledge Connection!


Video

Dr. Davidson on Leveraging Imaging Technologies to Inform Clinical Decisions in Breast Cancer

Nancy E. Davidson, MD, shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer.

Nancy E. Davidson, MD, the 2021 Giants of Cancer Care® award winner in Breast Cancer, senior vice president, director and professor, Clinical Research Division, Fred Hutch; Raisbeck Endowed Chair for Collaborative Research, Fred Hutch; and president and executive director, Seattle Cancer Care Alliance; shares how to leverage imaging technologies to inform treatment decisions in patients with breast cancer. 

Although there is much interest in both tissue and blood-born biomarkers of response in breast cancer, there has also been an increased interest in functional imaging techniques, according to Davidson. Currently, at the Fred Hutchinson Cancer Research Center, there is research being done to determine whether imaging technologies can be used to understand the biologic capacity of cancer in the patient. Efforts are being made to understand if this information can be utilized to determine whether a patient will respond to a particular treatment, Davidson adds. 

For example, new PET tracers make it possible to define hormone-responsive breast cancers more easily, Davidson notes. This is valuable, as it would shed light on a patient’s likelihood of responding to hormone therapy, and potentially inform whether focus should shift to other treatments that could be more beneficial, Davidson adds. This understanding would help prevent unnecessary exposure to hormone therapy and potential associated toxicities, Davidson concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Shilpa Gupta, MD, director of Genitourinary Medical Oncology at the Taussig Cancer Institute and co-leader of the Genitourinary Oncology Program in the Department of Hematology and Medical Oncology, Cleveland Clinic; as well as a member of the Developmental Therapeutics Program at the Case Comprehensive Cancer Center
Hyun-Woong Cho, MD, PhD, Department of Obstetrics and Gynecology, Korea University College of Medicine
SHAH
Timothy S. Fenske, MD, MS
Sheela Rao, MBBS, MD, FRCP
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD